Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 7/20 | 0.45 |
| ▸ | IL1B | P01584 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248525 | 0.95 | CASP1 (0.43) | CASP1IL1BCTSKFKBP1ASIRT5 | |
| SCHEMBL10201642 | 0.95 | CASP1 (0.52) | CASP1IL1BCTSKFKBP1ASIRT5 | |
| SCHEMBL10200529 | 0.88 | CASP1 (0.49) | CASP1IL1BCTSKALDH1A1 | |
| SCHEMBL10200531 | 0.87 | CASP1 (0.47) | CASP1IL1BCTSK | |
| SCHEMBL13139610 | 0.87 | CASP1 (0.55) | CASP1IL1BCTSKSIRT5ABCG2 | |
| SCHEMBL10200519 | 0.87 | CASP1 (0.56) | CASP1IL1BCTSK | |
| SCHEMBL10200532 | 0.87 | CASP1 (0.48) | CASP1IL1B | |
| SCHEMBL10200551 | 0.84 | CASP1 (0.48) | CASP1IL1BALDH1A1 | |
| SCHEMBL10200539 | 0.84 | CASP1 (0.43) | CASP1IL1B | |
| SCHEMBL10200526 | 0.83 | CASP1 (0.44) | CASP1IL1BCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885IL1B 3/4885CTSK 133/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CASP1 5/4885IL1B 2/4885CTSK 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.